GR5E

GR5E. It is a protein-coding gene located on the long arm of chromosome 17 in the human genome, identified through genome-wide association studies (GWAS). The gene is implicated in modulating cellular responses to oxidative stress and is thought to interact with pathways involving the NRF2 transcription factor. Research suggests its expression is influential in tissues with high metabolic demand, such as cardiac muscle and specific regions of the central nervous system.

Overview

The GR5E gene was first annotated following the completion of the Human Genome Project, with its locus refined through data from the ENCODE project. It is classified within a genomic region associated with several quantitative trait loci (QTLs) for metabolic parameters. Comparative genomics studies indicate that GR5E has orthologs in other mammals like Mus musculus and Rattus norvegicus, but appears absent in more distant species such as Drosophila melanogaster. Initial functional predictions were derived from bioinformatics analyses of its conserved protein domains, suggesting a role in redox homeostasis.

Structure and Function

The GR5E gene spans approximately 12 kilobases and consists of seven exons, which undergo alternative splicing to produce two major isoforms. The encoded protein is predicted to contain a Rossmann fold domain, indicative of nucleotide binding, and a zinc finger motif. Subcellular localization studies using confocal microscopy and green fluorescent protein (GFP) tagging have shown the primary isoform localizes to the mitochondrial matrix. Biochemical assays indicate the protein may act as a glutaredoxin or similar oxidoreductase, facilitating the reduction of protein disulfides in partnership with glutathione and thioredoxin reductase.

Clinical Significance

Variants within the GR5E locus have been associated with an increased susceptibility to Parkinson's disease in studies from the International Parkinson's Disease Genomics Consortium (IPDGC). Furthermore, certain single-nucleotide polymorphisms (SNPs) show correlation with altered progression in amyotrophic lateral sclerosis (ALS) in cohorts from the Project MinE data set. In oncology, reduced expression of GR5E has been observed in samples from The Cancer Genome Atlas (TCGA) for glioblastoma multiforme and pancreatic ductal adenocarcinoma, suggesting a potential role as a tumor suppressor gene in contexts of high reactive oxygen species (ROS).

Research and Applications

Current research on GR5E utilizes CRISPR-Cas9 gene editing in induced pluripotent stem cell (iPSC) models to elucidate its role in neurodegeneration. Collaborations between the Broad Institute and the Allen Institute for Brain Science are mapping its expression atlas in the mouse brain. Potential therapeutic applications are being explored, including the development of small molecule agonists that upregulate GR5E activity, with early-stage trials conducted by Biogen for multiple sclerosis. Its pathway is also a target in research on ischemia-reperfusion injury led by teams at the National Institutes of Health (NIH).

History and Discovery

The gene was initially flagged in a 2012 GWAS meta-analysis published in Nature Genetics investigating genetic links to essential tremor. The designation "GR5E" was assigned by the HUGO Gene Nomenclature Committee (HGNC) in 2015. Key early functional work was conducted by researchers at the University of Cambridge and the Karolinska Institutet, who demonstrated its induction under hydrogen peroxide treatment. The determination of its mitochondrial localization was a significant finding from a 2018 study in Cell Metabolism by scientists at the Max Planck Institute for Biology of Ageing.